Literature DB >> 32762546

Long Noncoding RNA TP53TG1 Contributes to Radioresistance of Glioma Cells Via miR-524-5p/RAB5A Axis.

Wenjin Gao1, Mu Qiao1, Kuan Luo1.   

Abstract

Background: Long noncoding RNAs (lncRNAs) have been reported to be important regulators in cancer. In this study, we aimed to discover the functions of lncRNA TP53TG1 in glioma.
Methods: The expression of lncRNA TP53TG1, microRNA-524-5p (miR-524-5p) and RAB5A, a member RAS oncogene family (RAB5A), were examined by quantitative real-time polymerase chain reaction. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and flow cytometry were applied to analyze the proliferation and apoptosis of glioma cells. Colony formation assay was used to detect the colony formation ability and radioresistance of glioma cells. Western blot assay was performed to detect the expression of autophagy-associated proteins and RAB5A. StarBase software was utilized to predict the combination between miR-524-5p and TP53TG1 or RAB5A, and dual-luciferase reporter assay and RNA immunoprecipitation assay were used to verify the above predictions. Animal experiment using immunodeficient nude mice was conducted to detect the role of TP53TG1 in vivo.
Results: Radiation stimulation (6 Gy) upregulated the abundance of TP53TG1. TP53TG1 potentiated radioresistance and progression of glioma by promoting the autophagy. miR-524-5p was verified as a direct downstream regulation of TP53TG1. miR-524-5p depletion attenuated the influence of TP53TG1 interference on the functions of glioma cells. RAB5A was a direct target of miR-524-5p as well. The inhibitory effect of miR-524-5p on the malignancy of glioma cells was overturned by overexpression of RAB5A. RAB5A was regulated by TP53TG1/miR-524-5p signaling in glioma cells. TP53TG1 silencing impeded the progression of glioma in vivo.
Conclusion: lncRNA TP53TG1 accelerated the proliferation, colony formation, autophagy, and radioresistance, and restrained the apoptosis of glioma cells through miR-524-5p/RAB5A axis.

Entities:  

Keywords:  RAB5A; TP53TG1; glioma; miR-524-5p; radioresistance

Mesh:

Substances:

Year:  2020        PMID: 32762546     DOI: 10.1089/cbr.2020.3567

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  6 in total

Review 1.  The Mechanism of Long Non-coding RNA in Cancer Radioresistance/Radiosensitivity: A Systematic Review.

Authors:  Wenhan Wu; Shijian Zhang; Jia He
Journal:  Front Pharmacol       Date:  2022-05-05       Impact factor: 5.988

2.  Systematic analyses identify the anti-fibrotic role of lncRNA TP53TG1 in IPF.

Authors:  Jian Sun; Yingying Guo; Tingting Chen; Tongzhu Jin; Lu Ma; Liqiang Ai; Jiayu Guo; Zhihui Niu; Ruoxuan Yang; Qianqian Wang; Xiaojiang Yu; Huiying Gao; Yuhan Zhang; Wei Su; Xiaoying Song; Weihang Ji; Qing Zhang; Mengqin Huang; Xingxing Fan; Zhimin Du; Haihai Liang
Journal:  Cell Death Dis       Date:  2022-06-04       Impact factor: 9.685

3.  Whole-genome-scale identification of novel non-protein-coding RNAs controlling cell proliferation and survival through a functional forward genetics strategy.

Authors:  D P Tonge; D Darling; F Farzaneh; G T Williams
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

4.  Knockdown of lncRNA TP53TG1 Enhances the Efficacy of Sorafenib in Human Hepatocellular Carcinoma Cells.

Authors:  Qingchun Lu; Mingyang Xin; Qian Guo; Brad S Rothberg; Ana M Gamero; Ling Yang
Journal:  Noncoding RNA       Date:  2022-08-10

5.  LncRNA TP53TG1 plays an anti-oncogenic role in cervical cancer by synthetically regulating transcriptome profile in HeLa cells.

Authors:  Yi Cheng; Nan Huang; Qingqing Yin; Chao Cheng; Dong Chen; Chen Gong; Huihua Xiong; Jing Zhao; Jianhua Wang; Xiaoyu Li; Jing Zhang; Shuangshuang Mao; Kai Qin
Journal:  Front Genet       Date:  2022-10-04       Impact factor: 4.772

6.  Long Non-Coding RNA TP53TG1 Upregulates SHCBP1 to Promote Retinoblastoma Progression by Sponging miR-33b.

Authors:  Hongyi Wang; Zhen Zhang; Yue Zhang; Shihai Liu; Li Li
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.